shenzhen salubris pharmaceuticals co., ltd.-凯发官网首页

news & trends

• 102022-11

  the marketing application of sal0107 for the treatment of primary hypertension was accepted

• 102022-11

  speeding up the innovation, salubris moves into the era of rna drugs

• 242022-10

  using ai-enabled drug discovery tools, salubris has partnered with alphamol to develop innovative drugs for obesity

• 172022-10

  clinical progress of sal0108 for the treatment of primary hypertension

• 132022-10

  clinical progress of sal056 for the treatment of osteoporosis

• 132022-10

  application for domestic clinical trial of sal008 injection was accepted